Skip to main content
. 2022 Nov 26;22:476. doi: 10.1186/s12905-022-02068-3

Table 2.

Clinical information and treatment of 16 patients with recurrent PEMa

Recurrent cases, No Number of lesions Size of lesions, cm ASIb Preoperative GnRH-ac Postoperative Hormone therapy Disease-free interval, mo Size of recurrent lesion, cm Treatment for recurrence
1 2 2.0; 1.5 MPAd 72 2 Bilateral oophorectomy and total hysterectomy
2 1 2.5 Y GnRH-a 96 3 Intravaginal radiation
3 2 5.0; 1.0 Y GnRH-a 3 3 Surgical excision, GnRH-a
4 1 2.5 30 3 Surgical excision, GnRH-a
5 1 2 Y Y Gestrinone 3 2.5 Surgical excision, GnRH-a
6 2 3.5; 2.5 Y Y GnRH-a 60 1.5 GnRH-a, COCse
7 2 4.0; 1.0 Y Y GnRH-a 15 2 LNG-IUSf
8 2 2.0; 1.0 Y COCs 24 1.5 GnRH-a, COCs
9 2 3.0; 1.5 Y Y 36 2.0, rectum involved Surgical excision, LNG-IUS
10 1 2.5 99 1.3 COCs
11 2 2.0; 1.0 Y Y LNG-IUS 6 3 GnRH-a, COCs, LNG-IUS
12 2 2.5; 1.0 GnRH-a 4 1 TCMg
13 1 3 Y Y GnRH-a 12 1.5 COCs
14 2 3.0; 2.0 Y Y 12 2 COCs
15 1 3 Y Y GnRH-a 6 1 LNG-IUS
16 2 2.0; 0.5 Y GnRH-a 26 3 Surgical excision, GnRH-a

aPEM perineal endometriosis; bASI anal sphincter involvement; cGnRH-a gonadotrophin-releasing hormone agonist; dMPA medroxyprogesterone acetate; eCOCs combined oral contraceptives; fLNG-IUS levonorgestrel-releasing intra-uterine system; gTCM: traditional chinese medicine